Aurinia Pharmaceuticals Inc. — Director's Dealing 2021

Jan 5, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-01-01

Reporting Person: Jayne David R.W. (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	30000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$3.62	2027-02-16	Common Stock (10000)		Direct
Stock Option (right to buy)	$6.95	2027-02-16	Common Stock (20000)		Direct
Stock Option (right to buy)	$5.14	2028-02-05	Common Stock (30000)		Direct
Stock Option (right to buy)	$6.06	2029-01-20	Common Stock (30000)		Direct
Stock Option (right to buy)	$6.42	2029-07-03	Common Stock (15000)		Direct
Stock Option (right to buy)	$15.75	2030-06-02	Common Stock (30000)		Direct

Footnotes

F1: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.

F2: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

F3: The shares subject to the option vest in twelve equal monthly installments from the grant date.